Related Experiment Videos
Remaining problems in the treatment of patients with Wilms' tumor
D M Green1, J Z Finklestein, N E Breslow
1Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, New York.
Pediatric Clinics of North America
|April 1, 1991
Abstract:
Major advances have been made in the treatment of children with Wilms' tumor. Remaining areas of investigation include the role of adriamycin and the treatment of children with stage III and IV disease and the role of whole lung radiation therapy in the treatment of children with pulmonary metastases. Long-term follow up of successfully treated patients will provide valuable insight into the importance of genetic factors in the cause of Wilms' tumor.
Insights
Advances in treating pediatric Wilms
Area of Science:
- Pediatric Oncology
- Nephroblastoma Research
Background:
- Wilms' tumor treatment has seen significant progress.
- Key areas for further investigation remain.
Purpose of the Study:
- To explore the role of adriamycin in Wilms' tumor therapy.
- To optimize treatment for advanced stages (III and IV) and pulmonary metastases.
- To understand the genetic factors influencing Wilms' tumor development.
Main Methods:
- Review of current treatment protocols for Wilms' tumor.
- Analysis of adriamycin efficacy.
- Evaluation of radiation therapy for pulmonary metastases.
- Long-term patient follow-up studies.
Main Results:
- Adriamycin's role in treatment requires further definition.
- Strategies for managing advanced Wilms' tumor and lung metastases are under investigation.
- Long-term outcomes are crucial for understanding disease etiology.
Conclusions:
- Continued research is essential for refining Wilms' tumor treatment protocols.
- Genetic factors may play a significant role in the development of Wilms' tumor.
- Further studies will enhance understanding and improve patient outcomes.